Showing results (71-80 of 1,205) with videos related to
Sort By:
Pageof 121
Annual Review of Pathology|February 8, 2018
Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver DiseaseJuan Pablo Arab, Marco Arrese, Michael TraunerCell Stress|June 30, 2025
Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative reviewKatharina Burger, Michael Michael Trauner, Ina BergheimCell Metabolism|October 8, 2022
Gut-liver axis: Pathophysiological concepts and clinical implicationsHerbert Tilg, Timon E Adolph, Michael TraunerHepatology (Baltimore, Md.)|April 3, 2020
The Role of Metabolic Lipases in the Pathogenesis and Management of Liver DiseaseMatteo Tardelli, Francesca Virginia Bruschi, Michael TraunerTrends in Endocrinology and Metabolism: TEM|September 4, 2014
Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLDClaudia D Fuchs, Thierry Claudel, Michael TraunerAtherosclerosis|September 29, 2009
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatmentTatjana Stojakovic, Thierry Claudel, Csilla Putz-Bankuti, et al.Gastroenterology|July 6, 2004
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout micePeter Fickert, Andrea Fuchsbichler, Martin Wagner, et al.Gut|February 26, 2021
From the origin of NASH to the future of metabolic fatty liver diseaseAndreas Geier, Dina Tiniakos, Helmut Denk, et al.Hepatology (Baltimore, Md.)|June 20, 2019
Liver Injury and Failure in Critical IllnessThomas Horvatits, Andreas Drolz, Michael Trauner, et al.Seminars in Liver Disease|February 13, 2016
Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver DiseaseClaudia D Fuchs, Stefan A Traussnigg, Michael TraunerPageof 121